Moderna stock could catch the eye of investors looking for the next big AI play, Revere Asset Management's Don Vandenbord says.

The market rally flashed some bearish signals. Moderna skyrocketed on a cancer vaccine while gold and bitcoin jumped. Walmart dived.

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the options chain hints at why this whipsaw is far from over.

JPMorgan layoffs hit highest since 2015, Amazon expands drone delivery, Chinese tech IPOs outshine U.S. rivals, and more news to start your day.

The home to some large pharma companies and many smaller biotechs, have risen over 6% this week. The main catalyst was that Moderna and Merck announced successful trial data for a melanoma vaccine that reduces the risk patients will experience recurrence. “The read-through [from Merck and Moderna] to the others is probably indicative of a broader tailwind of pharma taking some strong actions to improve their long-term growth profiles,” says Cantor Fitzgerald analyst Carter Gould.

Moderna shares rise to close out a week of wild swings, while crypto stocks extend their recent rally.

Former hedge fund manager Martin Shkreli revealed he was shorting Moderna Inc. at $80 per share just weeks before the biotech stock experienced a record-breaking 177% explosion on Thursday. Deconstructing the unexpected rally, the “Pharma Bro” admitted Wall Street was...

Moderna stole the show this week, but healthcare has been breaking out for months

Editor’s Note: The story has been refreshed with the latest market price action and a revised headline. Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of a...

The Morning Bull - US Market Morning Update Friday, Aug, 21 2026 US stock futures are slightly softer this morning, with E-mini S&P 500 contracts edging down about 0.1%, as investors digest a fresh mix of interest rate and bond market signals. The US Treasury plans to double its buybacks of long term bonds, which has pulled 30 year yields lower and is an attempt to ease the pressure from higher borrowing costs. At the same time, Federal Reserve minutes show some officials were ready to raise...

After ripping through the first half of the year, memory stocks are struggling to regain momentum as growing concerns about the state of the artificial intelligence trade overshadow their strong fundamental backdrop.

SELLAS Life Sciences Group (SLS) is drawing fresh attention as investors reassess immune based cancer therapy stocks following Moderna and Merck’s Phase 3 cancer vaccine update and the broader oncology rally it helped spark. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.40, SELLAS Life Sciences Group has seen a 72.24% 90 day share price return and a very large 1 year total shareholder return. This suggests momentum has been building as attention shifts...

The Nasdaq closed below its Aug. 4 follow-through day low, a highly bearish signal for the market rally. Walmart, SpaceX, CrowdStrike were big losers.

Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.

Moderna (MRNA) is back in focus after reporting that its personalized mRNA cancer therapy intismeran achieved primary and key secondary goals in a large Phase 3 melanoma trial, outperforming standard immunotherapy alone. See our latest analysis for Moderna. Following the trial update, Moderna’s recent share price moves have been sharp, with a 7 day share price return of 109.44% and a year to date share price return of 331.98%, while the 1 year total shareholder return is 408.43%. This...

The Nasdaq Composite fell 1%. The bond market was a major reason stocks took a tumble. Treasury yields rose on Thursday, with the 30-year Treasury bond reaching 5.25% and the 10-year reaching 4.7% (bond prices and yields move inverse to each other).

Breaking news: Moderna isn't just a "pandemic stock" after all.

Find insight on Moderna, Merck KGaA, Novonesis and more in the latest Market Talks covering the health care sector.

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the stock surged over 175% in the previous session on positive clinical trial news.

BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI to $80 from $70 and kept a Buy rating.

Cathie Wood's ARK Invest launched a new autocallable ETF that tracks the firm's other funds, which hold stocks like Tesla, Palantir and AMD.

A new mRNA cancer vaccine hit its goal in melanoma patients, giving a healthcare giant a fresh growth story.

Moderna stock soared 177% after a major cancer vaccine breakthrough. See Wall Street’s latest MRNA price targets and whether the rally can continue.

Moderna Inc (NASDAQ:MRNA, XETRA:0QF)'s melanoma trial success is prompting Wall Street to assign new platform value to the company's oncology pipeline, Jefferies said, as investors look beyond its COVID-dependent revenue base. The Jefferies note said intismeran vipatamotide (mRNA-4157), an...

Moderna and Merck scored a big win for their cancer vaccine on Wednesday. But analysts say it's too early to call it a home run.

Moderna's mRNA cancer vaccine sent shares on one of biotech's wildest two-day rides in years, but the brutal Thursday reversal raises a question investors now have to answer: does the science justify what the market priced in?

Stock Market Today: The Dow Jones index drops Thursday on Trump's "Economic D-Day" threat on Iran. Walmart dives on earnings.

The day after Moderna’s stock posted its biggest one-day gain on record, it is on track for its largest percent drop in more than two years as investors digested the news and adjusted their positions. Prior to Wednesday’s rally on positive mRNA cancer vaccine data, Moderna’s stock had substantial short interest at 13.7%. UBS said its clients sold a record $44 million in Moderna shares Wednesday, suggesting some investors were cashing out after the rally.

Moderna (MRNA) shares jumped after the company reported positive results from a late-stage trial of its personalized melanoma vaccine. Bernstein senior analyst of US Biopharmaceuticals Courtney Breen joins Julie Hyman on Market Catalysts to break down the trial results, what’s driving the stock move, and the potential pricing opportunity for Moderna’s cancer vaccine.

Hedge funds are quietly loading up on a battered pharma giant while yield hunters circle its once-near-7% dividend, but with a 14% rally already in the books and patent cliffs looming, the real question is whether the smart money spotted a turning point or a trap.

RBC Capital Markets analyst Trung Huynh downgrades shares of the Keytruda maker following a nearly 13% rally.

Shares of Moderna (NASDAQ:MRNA) stock are down 18% to $142.70 in Thursday midday trading, unwinding a meaningful piece of Wednesday’s historic 177% rally. The reversal follows a Phase 3 win for Moderna’s personalized cancer vaccine, a result that repriced Moderna stock so violently in one session that a retrace looked close to inevitable. BioNTech (NASDAQ:BNTX) ... Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips

Merck and Moderna's personalized melanoma therapy meet key goals in phase III study, improving recurrence-free and distant metastasis-free survival in high-risk patients.

Moderna (MRNA) and Merck (MRK) reported promising results in their melanoma vaccine trial, sending the stocks soaring. BD8 Capital Partners CEO and CIO Barbara Doran and Yahoo Finance Markets and Data Editor Jared Blikre chat with Yahoo Finance Executive Editor Brian Sozzi about what the breakthrough could mean for Pfizer (PFE) and the larger healthcare sector.

Moderna declines after skyrocketing the previous session. Walmart falls as guidance fails to impress.

RBC Capital noted that while the cancer vaccine results exceeded expectations, the stock’s $150 valuation is ‘unprecedented’ for a company facing a major loss of exclusivity in two years.

A landmark trial success for Moderna and Merck's cancer vaccine has strengthened the case for Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the immuno-oncology company developing a rival melanoma treatment, according to one broker covering the sector's innovative small-caps. Merck and...

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.5% and the actively tr

MRNA's cancer therapy scores a first phase III win, fueling hopes its mRNA platform can drive growth beyond COVID-19 vaccines.

Many Fed officials favor raising rates to combat inflation, bond prices surge, Trump meets crypto execs, and more news to start your day.

News of the day for Aug. 20, 2026

The stock jumps after a melanoma treatment has success in a late-stage trial. One analyst says annual sales could hit $3 billion by 2035.

Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest.

Dow Jones futures: Crude oil continues to climb while bitcoin jumped again amid a weak dollar. Walmart earnings are in focus.

In August 2026, Merck and Moderna reported that their Phase 3 INTerpath-001 trial showed that individualized mRNA therapy intismeran (V940/mRNA-4157) plus KEYTRUDA improved recurrence-free and distant metastasis-free survival in patients with completely resected stage IIB–IV melanoma versus KEYTRUDA alone. This marks the first successful Phase 3 result for both an individualized neoantigen mRNA cancer therapy and an mRNA treatment outperforming a standard-of-care immunotherapy in the...

CANC hits a 52-week high as strong oncology developments and positive momentum fuel the biotech ETF's rally.

Companies In The Article Are:MRNA,MRK,MRVL,GOOG,TGT and LOW

Investing.com -- Moderna shares pulled back sharply on Thursday, giving up a small chunk of Wednesday’s record-breaking rally after the stock rocketed as much as 177% on data showing its personalized cancer vaccine, developed with Merck, slowed the spread and recurrence of melanoma. Merck shares had jumped 12.6% on Wednesday alongside Moderna’s surge.

By Mike Dolan Aug 20 (Reuters) - What matters in U.S. and global markets today By Mike Dolan, Editor-at-Large, Finance and Markets Buybacks to the rescue? The surprising move by the U.S.

Moderna (NASDAQ:MRNA) shares fell sharply in premarket trading on Thursday as investors took profits following the biggest one-day rally in the biotechnology company’s history, while concerns over valuation added to the selling pressure. The stock dropped 13.